About this policy
The comment period for the Response to Comments: MolDX: Breast Cancer IndexTM (BCI) Gene Expression Test DL37822 began on 10/04/2018 and ended on 12/14/2018. Comments were received from the provider community. The notice period begins on 02/28/2019 and ends 04/15/2019. The LCD becomes final on 04/16/2019.
Codes in this policy
Code numbers and each code’s status as the policy records it. CPT code descriptions are left out of this page, as are the passages that cite CPT codes; the official document has them.
Backwork has no codes on record for this policy. Check the source.